AR033465A1 - El uso de un antagonista del receptor de endotelina en la fabricacion de un medicamento util en la modulacion favorable de la calidad de vida relacionada con la salud y progresion temporal ajustada a la calidad relacionada con la salud de una enfermedad en pacientes con cancer de prostata - Google Patents

El uso de un antagonista del receptor de endotelina en la fabricacion de un medicamento util en la modulacion favorable de la calidad de vida relacionada con la salud y progresion temporal ajustada a la calidad relacionada con la salud de una enfermedad en pacientes con cancer de prostata

Info

Publication number
AR033465A1
AR033465A1 ARP020101335A ARP020101335A AR033465A1 AR 033465 A1 AR033465 A1 AR 033465A1 AR P020101335 A ARP020101335 A AR P020101335A AR P020101335 A ARP020101335 A AR P020101335A AR 033465 A1 AR033465 A1 AR 033465A1
Authority
AR
Argentina
Prior art keywords
health
quality
adjusted
endotheline
manufacture
Prior art date
Application number
ARP020101335A
Other languages
English (en)
Spanish (es)
Inventor
Singh Robert J Padley Amitabh
Ashraf Talat
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/832,752 external-priority patent/US20030022811A1/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR033465A1 publication Critical patent/AR033465A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP020101335A 2001-04-11 2002-04-11 El uso de un antagonista del receptor de endotelina en la fabricacion de un medicamento util en la modulacion favorable de la calidad de vida relacionada con la salud y progresion temporal ajustada a la calidad relacionada con la salud de una enfermedad en pacientes con cancer de prostata AR033465A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/832,752 US20030022811A1 (en) 2001-04-11 2001-04-11 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
US11848602A 2002-04-08 2002-04-08

Publications (1)

Publication Number Publication Date
AR033465A1 true AR033465A1 (es) 2003-12-17

Family

ID=26816420

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101335A AR033465A1 (es) 2001-04-11 2002-04-11 El uso de un antagonista del receptor de endotelina en la fabricacion de un medicamento util en la modulacion favorable de la calidad de vida relacionada con la salud y progresion temporal ajustada a la calidad relacionada con la salud de una enfermedad en pacientes con cancer de prostata

Country Status (10)

Country Link
EP (1) EP1379238A1 (enExample)
JP (1) JP2005503339A (enExample)
CN (1) CN1514727A (enExample)
AR (1) AR033465A1 (enExample)
BR (1) BR0205970A (enExample)
CA (1) CA2442591A1 (enExample)
IL (1) IL158071A0 (enExample)
MX (1) MXPA03009277A (enExample)
PE (1) PE20021032A1 (enExample)
WO (1) WO2002085351A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
WO2004100991A1 (en) * 2003-05-15 2004-11-25 Universite Catholique De Louvain Use of endothelin-1 antagonists for improving cancer therapy
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
JP2009537535A (ja) * 2006-05-15 2009-10-29 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド エンドセリンアンタゴニストの投与を含む睡眠時無呼吸を治療するための方法および組成物
EP2545920A1 (en) 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes
CN117751099A (zh) * 2021-08-05 2024-03-22 中国药科大学 酰胺类化合物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200101234T2 (tr) * 1997-08-04 2002-06-21 Abbott Laboratories Endotelin antagonistleri.

Also Published As

Publication number Publication date
MXPA03009277A (es) 2004-03-10
EP1379238A1 (en) 2004-01-14
CN1514727A (zh) 2004-07-21
BR0205970A (pt) 2003-09-30
JP2005503339A (ja) 2005-02-03
IL158071A0 (en) 2004-03-28
PE20021032A1 (es) 2002-11-12
CA2442591A1 (en) 2002-10-31
WO2002085351A1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
CY1121134T1 (el) Συνθεσεις και μεθοδοι για την τροποποιηση της smn2 συγκολλησης
CY1109119T1 (el) Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης που περιλαμβανουν λαμοτριγινη
CY1114139T1 (el) Πλακιδιο βουπρενορφινης για τη θεραπεια υποκαταστασης ναρκωτικων
CY1110721T1 (el) Χρηση glp-2 σε συνδυασμο με αλλο θεραπευτικο παραγοντα σε οστικες παθησεις
UY27939A1 (es) Compuestos
ECSP045069A (es) Uso de flibanserina en el tratamiento de trastornos sexuales
NZ544472A (en) Compounds and therapeutical use thereof
AR094217A2 (es) Monoetanosulfonato de 3-z-[1-(4-(n-((4-metil-piperazina-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metilen]-6-metoxicarbonil-2-indolinona y su utilizacion como medicamento
WO2004059285A3 (en) Tumor killing/tumor regression using cxcr4 antagonists
AU2003267581A8 (en) Drug delivery
NO20022065L (no) Terapeutisk anvendelse
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
AR033465A1 (es) El uso de un antagonista del receptor de endotelina en la fabricacion de un medicamento util en la modulacion favorable de la calidad de vida relacionada con la salud y progresion temporal ajustada a la calidad relacionada con la salud de una enfermedad en pacientes con cancer de prostata
AR037343A1 (es) Uso de antagonistas del receptor de endotelina para la preparacion de un medicamento destinado al tratamiento de enfermedades tumorales
TW200509896A (en) Analeptic and drug combinations
TW200642704A (en) Oral drug delivery system and methods of use thereof
ATE411981T1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
TR199902980T2 (xx) Diabetin tedavisi i�in leptin antagonistlerinin kullan�m�.
AR041595A1 (es) Tratamiento terapeutico
AR032422A1 (es) Uso de inhibidores de il-18 para el tratamiento y/o prevencion de la enfermedad cardiaca
AR031122A1 (es) Uso de antagonistas de endotelina en la fabricacion de medicamentos utiles para el tratamiento del cancer y el dolor asociado con el mismo
UY27257A1 (es) Composición farmacéutica para su uso en la modulación favorable de la calidad de vida relacionada con la salud y progresión temporal ajustada a la calidad relacionada con la salud de una enfermedad en pacientes con cáncer de próstata
ECSP034636A (es) Uso de 6-dimetilaminometil-1-fenil-ciclohexaco sustituido en la terapia de la incontinencia urinaria
PL1713438T3 (pl) Mydło lecznicze
EP1550720A4 (en) MUTATED ANDROGEN RECEPTOR, THESE EXPRESSING CANCER CELLS, METHOD OF CONSTRUCTING THEREOF, AND USE THEREOF

Legal Events

Date Code Title Description
FA Abandonment or withdrawal